Why did Eli Lilly transfer commercialization rights for Verzenios in mainland China?

Eli Lilly transferred the mainland China commercialization rights for Verzenios to Innovent Biologics amid generic competition, following local approval of a generic version from a unit of China's Qingfeng Pharmaceutical Group this year.

What responsibilities will Eli Lilly retain for Verzenios in China after the transfer?

After the transfer, Eli Lilly will continue manufacturing, supplying, and developing Verzenios in mainland China, while Innovent holds sole commercialization rights.

Eli Lilly transfers commercialization rights for breast cancer drug in China amid generic competition

Jun 29, 2026

Eli Lilly transferred mainland China commercialization rights for its breast cancer drug Verzenios to Innovent Biologics due to generic competition. Lilly will continue manufacturing and supplying the drug while Innovent handles sales.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks